Literature DB >> 29190907

Profile of differentially expressed Toll-like receptor signaling genes in the natural killer cells of patients with Sézary syndrome.

Kelly C G ManfrereC1, Marina P Torrealba1, Denis R Miyashiro2, Nátalli Z Pereira1, Fabio S Y Yoshikawa1, Luana de M Oliveira1, Jade Cury-Martins2, Alberto J S Duarte1, José A Sanches2, Maria N Sato1.   

Abstract

Sézary syndrome (SS), an aggressive and leukemic form of cutaneous T-cell lymphoma, usually results in shortened survival. Improving innate immunity in SS by targeting natural killer (NK) cells with Toll-like receptor (TLR) agonists could be an interesting modulatory strategy. We evaluated the NK cell populations in SS patients assessing activating and inhibitory receptors expression and profiled the differential expression of TLR signaling pathway genes in unstimulated NK cells and after TLR7/8 stimulation. We observed preserved CD56bright NK cells and a low percentage of CD56dim NK cells in the peripheral blood of SS patients compared to those in the healthy control group. Both NK cell populations showed down-modulation of NKG2C and NKG2D expression, which was associated with high serum levels of the soluble form of NKG2D ligands. In contrast, an expansion of "memory" CD57+ NKG2C+ NK cells and high cytomegalovirus antibody titers were detected in SS patients. Profiling of the TLR signaling genes in NK cells from SS patients showed an abundance of differentially expressed genes (DEGs) in NK cells in the unstimulated condition, with mostly up-regulation of NFκB/JNK p38 pathway genes, but there was down-regulation of type I (IFN-α/β) and II (IFN-γ) interferon and IL-12A. After activation of NK cells with TLR7/8 agonist, the down-regulated genes correlated with the IFN response, and IL-12 became up-regulated, together with other antitumor factors. NK cell activation with a dual agonist for TLR7 and TLR8 is able to induce the expression of IFN-γ and type I IFN, which can improve immunity in SS patients.

Entities:  

Keywords:  Sézary syndrome; Toll-like receptor 7/8; differentially expressed genes; memory NK cells; natural killer cells

Year:  2017        PMID: 29190907      PMCID: PMC5696173          DOI: 10.18632/oncotarget.21006

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


  62 in total

1.  Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases.

Authors:  E Stockfleth; T Meyer; B Benninghoff; E Christophers
Journal:  Br J Dermatol       Date:  2001-05       Impact factor: 9.302

Review 2.  The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma.

Authors:  Natalie Spaccarelli; Alain H Rook
Journal:  Dermatol Clin       Date:  2015-08-20       Impact factor: 3.478

3.  Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.

Authors:  Neil Korman; Ron Moy; Mark Ling; Robert Matheson; Stacy Smith; Scott McKane; James H Lee
Journal:  Arch Dermatol       Date:  2005-04

Review 4.  The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.

Authors:  John P Vasilakos; Mark A Tomai
Journal:  Expert Rev Vaccines       Date:  2013-07       Impact factor: 5.217

5.  IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion.

Authors:  Alexander Rölle; Julia Pollmann; Eva-Maria Ewen; Vu Thuy Khanh Le; Anne Halenius; Hartmut Hengel; Adelheid Cerwenka
Journal:  J Clin Invest       Date:  2014-11-10       Impact factor: 14.808

Review 6.  CD57 in human natural killer cells and T-lymphocytes.

Authors:  Hassen Kared; Serena Martelli; Tze Pin Ng; Sylvia L F Pender; Anis Larbi
Journal:  Cancer Immunol Immunother       Date:  2016-02-05       Impact factor: 6.968

7.  IRF-1 expression is essential for natural killer cells to suppress metastasis.

Authors:  Antje Ksienzyk; Berit Neumann; Ramya Nandakumar; Katja Finsterbusch; Martina Grashoff; Rainer Zawatzky; Günter Bernhardt; Hansjörg Hauser; Andrea Kröger
Journal:  Cancer Res       Date:  2011-09-07       Impact factor: 12.701

Review 8.  TLR7 and TLR8 as targets in cancer therapy.

Authors:  M P Schön; M Schön
Journal:  Oncogene       Date:  2008-01-07       Impact factor: 9.867

9.  KIR3DL2/CpG ODN interaction mediates Sézary syndrome malignant T cell apoptosis.

Authors:  Bouchra Ghazi; Nicolas Thonnart; Martine Bagot; Armand Bensussan; Anne Marie-Cardine
Journal:  J Invest Dermatol       Date:  2014-07-09       Impact factor: 8.551

10.  Aberrant expression of T-plastin in Sezary cells.

Authors:  Ming-wan Su; Irene Dorocicz; Wieslawa H Dragowska; Vincent Ho; Gang Li; Nicolas Voss; Randy Gascoyne; Youwen Zhou
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

View more
  1 in total

Review 1.  The Role of Tumor Microenvironment in the Pathogenesis of Sézary Syndrome.

Authors:  Denis Miyashiro; Bruno de Castro E Souza; Marina Passos Torrealba; Kelly Cristina Gomes Manfrere; Maria Notomi Sato; José Antonio Sanches
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.